IMMUNITYBIO, INC. Accrued Liabilities, Current
IMMUNITYBIO, INC. (IBRX) had Accrued Liabilities, Current of $48.20 million as of 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-05-07
- 2026-03-31: Accrued Liabilities, Current $48.20M.
- 2025-12-31: Accrued Liabilities, Current $46.84M.
- 2025-09-30: Accrued Liabilities, Current $43.60M.
- 2025-06-30: Accrued Liabilities, Current $35.70M.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-03-31 | $48.20M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $46.84M 10-Q · filed 2026-05-07 | |
| 2025-09-30 | $43.60M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $35.70M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $27.89M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $40.58M 10-K · filed 2026-02-23 | |
| 2024-09-30 | $43.60M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $35.34M 10-Q · filed 2024-08-12 | |
| 2024-03-31 | $32.71M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $42.71M 10-K · filed 2025-03-03 | |
| 2023-09-30 | $64.87M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $62.34M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $54.12M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $41.83M 10-K · filed 2024-03-19 | |
| 2022-09-30 | $46.22M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $52.35M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $62.47M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $51.39M 10-K · filed 2023-03-01 | |
| 2021-09-30 | $38.52M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $36.13M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $36.79M 10-Q · filed 2021-05-14 | |
| 2020-12-31 | $36.77M 10-K · filed 2022-03-01 | $8.34M 10-K · filed 2021-03-04 |
| 2020-09-30 | $5.50M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $7.45M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $6.63M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $23.48M 8-K/A · filed 2021-04-22 | $5.34M 10-K · filed 2020-03-25 |
| 2019-09-30 | $5.25M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $6.47M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $20.24M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $21.10M 10-K · filed 2020-03-25 | |
| 2018-09-30 | $22.79M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $11.52M 10-Q · filed 2018-08-06 | |
| 2018-03-31 | $12.08M 10-Q · filed 2018-05-07 | |
| 2017-12-31 | $11.27M 10-K · filed 2019-03-13 | |
| 2017-09-30 | $15.84M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $14.38M 10-Q · filed 2017-08-07 | |
| 2017-03-31 | $6.86M 10-Q · filed 2017-05-08 | |
| 2016-12-31 | $5.86M 10-K · filed 2018-03-12 | |
| 2016-09-30 | $5.91M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | $4.72M 10-Q · filed 2016-08-15 | |
| 2016-03-31 | $4.72M 10-Q · filed 2016-05-16 | |
| 2015-12-31 | $2.58M 10-K · filed 2017-03-15 | |
| 2015-09-30 | $1.13M 10-Q · filed 2015-11-12 | |
| 2015-06-30 | $2.62M 10-Q · filed 2015-09-10 | |
| 2014-12-31 | $311.00K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |